Drug Pipeline

LXH254 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
4
Active Studies
0
Recruiting
1
Phase 3
2
Top Sponsors
Active Studies by Phase
Phase 3
1
Phase 2
1
Phase 1
2
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT06346067 A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With… Advanced or Metastatic NRAS-mutant Melanoma Active, Not Recruiting
Phase 2
NCT04417621 Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated… Melanoma Active, Not Recruiting
Phase 1
NCT03333343 Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC EGFR-mutant Non-small Cell Lung Cancer Active, Not Recruiting
NCT05907304 A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With… Advanced or Metastatic Solid Tumors Active, Not Recruiting
Sponsors Running LXH254 Trials
Novartis Pharmaceuticals (2) Erasca, Inc. (2)
Disease Areas
Melanoma (2) Non-Small Cell Lung Cancer (NSCLC) (1) Lung Cancer (1)
Get alerts when LXH254 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free